Cytek Biosciences Inc (CTKB)
Financial leverage ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Total assets | US$ in thousands | 499,500 | 494,457 | 519,476 | 463,700 | 219,979 |
| Total stockholders’ equity | US$ in thousands | 395,737 | 393,064 | 425,295 | 406,458 | -16,028 |
| Financial leverage ratio | 1.26 | 1.26 | 1.22 | 1.14 | — |
December 31, 2024 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $499,500K ÷ $395,737K
= 1.26
Cytek Biosciences Inc's financial leverage ratio has been gradually increasing over the years, reaching 1.26 at the end of both 2023 and 2024. This indicates that the company's reliance on debt to finance its operations and growth has also been increasing. A financial leverage ratio of 1.26 means that the company's total assets are financed by 1.26 times its total debt. It is important to closely monitor this trend as higher leverage can amplify returns on equity in good times but can also pose risks during economic downturns or periods of financial stress. Investors and creditors should assess Cytek Biosciences Inc's ability to comfortably meet its debt obligations and manage potential risks associated with its increasing leverage ratio.
Peer comparison
Dec 31, 2024